TVRD
Tvardi Therapeutics, Inc.
$2.64
-2.58%
$24.8M
No data for this timeframe.
Vol
Market Cap$24.8M
Cap SizeNano Cap
Analyst ConsensusBuy (64%)
Inst. Holders29 funds
Inst. Value$4.2M
Inst. Activity5 buys / 1 sells
SEC Reports5
Recent Activity
Jun 9, 2026
Insider
Shiff Susan Ph.D. was granted 6,000 shares
Director
Jun 9, 2026
Insider
Smith Cynthia was granted 6,000 shares
Director
May 19, 2026
earnings_calendar
TVRD Q1 2026 Earnings Scheduled — 2026-05-19
May 14, 2026
SEC
Tvardi Therapeutics' S-3 shelf registration (File No. 333-287675) became effective on May 13, 2026. The shelf allows the
EFFECT — Impact 6/10
May 13, 2026
SEC
Tvardi Therapeutics' S-3 registration statement has been declared effective, allowing the company to sell up to $200 mil
EFFECT — Impact 7/10
May 8, 2026
SEC
Tvardi Therapeutics reported Q1 2026 EPS of -$0.73, missing consensus of -$0.72 by 1.4% (in-line), with no revenue. The
PRESS-RELEASE — Impact 4/10
Jan 29, 2026
Insider
Alibhai Imran Nizamudin was granted 115,000 shares
Chief Executive Officer
Inst.
Russell Investments Group, Ltd. — ADD
23,307 shares ($74.1K)
Price Targets
$8.29
+213.9% upside
Strong Buy
Current $2.64
Low $3.00
Median $9.00
High $15.00
7 analysts
$3.00
$15.00
Analyst Ratings
4Strong Buy
5Buy
4Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | INITIATE | Buy |
| Apr 20, 2026 | Barclays | DOWNGRADE | Equal-Weight → Underweight |
| Apr 1, 2026 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
| Apr 1, 2026 | Piper Sandler | MAINTAIN | Neutral → Neutral |
| Apr 1, 2026 | BTIG | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.63 | $-0.78 — $-0.41 | -224% YoY | 7 |
| Next Q | $-0.54 ▼ -23.0% | $-0.86 — $-0.32 | 9% YoY | 7 |
| Current FY | $-2.39 ▼ -20.9% | $-3.54 — $-1.72 | 3% YoY | 7 |
| Next FY | $-2.89 ▼ -26.2% | $-6.52 — $-0.56 | -21% YoY | 7 |
Latest Reports
BEARISH
EFFECT
6/10
Tvardi Therapeutics' S-3 shelf registration (File No. 333-287675) became effective on May 13, 2026. The shelf allows the
May 14, 2026
BEARISH
EFFECT
7/10
Tvardi Therapeutics' S-3 registration statement has been declared effective, allowing the company to sell up to $200 mil
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| BlackRock, Inc. | $1.2M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.1M | — |
| SILVERCREST ASSET MANAGEMENT GROUP | $321.3K | DOUBLED |
| STATE STREET CORP | $309.2K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Shiff Susan | A | $0.00 |
| Jun 9, 2026 | Smith Cynthia | A | $0.00 |
| Jan 29, 2026 | Alibhai Imran | A | $0.00 |
| Jan 29, 2026 | Conn Avi | A | $0.00 |
| Jan 29, 2026 | O'Brien Stephen | A | $0.00 |
29 institutional holders with $4.2M total value (1,317,486 shares) as of 2026-Q1. Top holders: ROYAL, BlackRock,, VANGUARD. Net buying activity: 5 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 85 | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 388,075 | $1.2M | 29.5% | — |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 344,708 | $1.1M | 26.2% | — |
| 4 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 101,034 | $321.3K | 7.7% | DOUBLED +351.7% |
| 5 | STATE STREET CORP | 97,231 | $309.2K | 7.4% | ADD +83.7% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 92,100 | $292.9K | 7.0% | DOUBLED +246.3% |
| 7 | MORGAN STANLEY | 72,894 | $231.8K | 5.5% | DOUBLED +2131.0% |
| 8 | VANGUARD FIDUCIARY TRUST CO | 46,872 | $149.1K | 3.6% | — |
| 9 | GREAT LAKES ADVISORS, LLC | 36,236 | $115.2K | 2.8% | — |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 33,833 | $107.6K | 2.6% | — |
| 11 | GOLDMAN SACHS GROUP INC | 23,898 | $76.0K | 1.8% | — |
| 12 | Russell Investments Group, Ltd. | 23,307 | $74.1K | 1.8% | ADD +46.0% |
| 13 | FARALLON CAPITAL MANAGEMENT LLC | 21,438 | $68.2K | 1.6% | TRIM -50.4% |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 11,784 | $37.5K | 0.9% | ADD +26.7% |
| 15 | FMR LLC | 5,278 | $16.8K | 0.4% | NEAR_EXIT -92.0% |
| 16 | Vanguard Global Advisers, LLC | 3,400 | $10.8K | 0.3% | — |
| 17 | RHUMBLINE ADVISERS | 3,244 | $10.3K | 0.2% | — |
| 18 | DEUTSCHE BANK AG\ | 3,030 | $9.6K | 0.2% | — |
| 19 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 2,356 | $7.5K | 0.2% | — |
| 20 | WELLS FARGO & COMPANY/MN | 2,266 | $7.2K | 0.2% | ADD +69.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Russell Investments Group, Ltd. | ADD | 15,966 | 23,307 | +46.0% | $74.1K | 2026-Q1 |
| FARALLON CAPITAL MANAGEMENT LLC | TRIM | 43,225 | 21,438 | -50.4% | $68.2K | 2026-Q1 |
| CWM, LLC | DOUBLED | 206 | 1,706 | +728.2% | $5.4K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 294 | 519 | +76.5% | $1.6K | 2026-Q1 |
| GROUP ONE TRADING LLC | ADD | 114 | 214 | +87.7% | $681.00 | 2026-Q1 |
| Allworth Financial LP | ADD | 141 | 206 | +46.1% | $656.00 | 2026-Q1 |
| STATE STREET CORP | ADD | 62,864 | 115,501 | +83.7% | $496.7K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 30,175 | 104,500 | +246.3% | $449.4K | 2025-Q4 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | DOUBLED | 22,366 | 101,034 | +351.7% | $434.4K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 3,786 | 84,466 | +2131.0% | $363.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 15,362 | 25,382 | +65.2% | $109.1K | 2025-Q4 |
| Russell Investments Group, Ltd. | DOUBLED | 1,100 | 15,966 | +1351.5% | $68.7K | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 82,221 | 6,599 | -92.0% | $28.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 3,554 | 6,033 | +69.8% | $25.9K | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 48 | 294 | +512.5% | $1.3K | 2025-Q4 |
| Allworth Financial LP | DOUBLED | 19 | 141 | +642.1% | $607.00 | 2025-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 14 | 114 | +714.3% | $490.00 | 2025-Q4 |
| CWM, LLC | DOUBLED | 5 | 206 | +4020.0% | $1.00 | 2025-Q4 |
| FMR LLC | DOUBLED | 5 | 82,221 | +1644320.0% | $3.2M | 2025-Q3 |
| STATE STREET CORP | ADD | 41,529 | 62,864 | +51.4% | $2.4M | 2025-Q3 |
| UBS Group AG | ADD | 29,353 | 48,479 | +65.2% | $1.9M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 12,052 | 15,274 | +26.7% | $595.2K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 2,509 | 3,554 | +41.7% | $138.5K | 2025-Q3 |
| Legal & General Group Plc | ADD | 310 | 421 | +35.8% | $16.4K | 2025-Q3 |
6 unique insiders with 6 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Shiff Susan Ph.D. | Director | AWARD | 6,000 | — | — |
| Jun 9, 2026 | Smith Cynthia | Director | AWARD | 6,000 | — | — |
| Jan 29, 2026 | Alibhai Imran Nizamudin | Chief Executive Officer | AWARD | 115,000 | — | — |
| Jan 29, 2026 | Conn Avi Daniel | Chief Financial Officer | AWARD | 45,000 | — | — |
| Jan 29, 2026 | O'Brien Stephen Paul | Principal Accounting Officer | AWARD | 15,000 | — | — |
| Jan 29, 2026 | Kauh John Saewook M.D. | Chief Medical Officer | AWARD | 45,000 | — | — |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 1 mixed, 2 neutral. Avg impact: 5.0/10.
BEARISH
EFFECT
6/10
Tvardi Therapeutics' S-3 shelf registration (File No. 333-287675) became effective on May 13, 2026.
May 14, 2026
BEARISH
EFFECT
7/10
Tvardi Therapeutics' S-3 registration statement has been declared effective, allowing the company to
May 13, 2026
NEUTRAL
PRESS-RELEASE
4/10
Tvardi Therapeutics reported Q1 2026 EPS of -$0.73, missing consensus of -$0.72 by 1.4% (in-line), w
May 8, 2026
NEUTRAL
DEFA14A
2/10
Tvardi Therapeutics, Inc. has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeti
Apr 23, 2026
MIXED
8-K
6/10
Tvardi Therapeutics reported Q4 2025 net loss per share of $0.78, missing consensus of $0.72, on red
Apr 21, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (64% buy). Based on 14 analysts: 4 strong buy, 5 buy, 4 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$8.29 mean target
+213.9% upside
Strong Buy (2.00)
$3.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $2.64 |
| Target Low | $3.00 |
| Target Mean | $8.29 |
| Target Median | $9.00 |
| Target High | $15.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.63 | $-0.78 | $-0.41 | -223.8% | +0.3% | 3↑ 1↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.54 | $-0.86 | $-0.32 | 9.0% | -23.0% | 2↑ 1↓ | $0.0B | 0.0% | 7 |
| Current FY 2026-12-31 |
$-2.39 | $-3.54 | $-1.72 | 2.8% | -20.9% | 3↑ 2↓ | $0.0B | 0.0% | 7 |
| Next FY 2027-12-31 |
$-2.89 | $-6.52 | $-0.56 | -20.8% | -26.2% | 5↑ 0↓ | $0.0B | 0.0% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.631 | |
| 7d ago | $-0.607 | -0.025 |
| 30d ago | $-0.633 | +0.002 |
| 60d ago | $-0.682 | +0.051 |
| 90d ago | $-0.635 | +0.004 |
4 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
| Apr 20, 2026 | Barclays | DOWNGRADE | Equal-Weight | Underweight |
| Apr 1, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 1, 2026 | Piper Sandler | MAINTAIN | Neutral | Neutral |
| Apr 1, 2026 | BTIG | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 4 | 1 | 0 | 64% | |
| May 1, 2026 | 4 | 5 | 4 | 1 | 0 | 64% | |
| Apr 1, 2026 | 4 | 5 | 5 | 0 | 0 | 64% | |
| Mar 1, 2026 | 4 | 5 | 5 | 0 | 0 | 64% | |
| Feb 1, 2026 | 4 | 4 | 6 | 0 | 0 | 57% | |
| Jan 1, 2026 | 4 | 4 | 6 | 0 | 0 | 57% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
earnings_calendar
TVRD Q1 2026 Earnings Scheduled — 2026-05-19
May 8, 2026
earnings
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
<p align="center"><em>Topline results from healthy volunteer study and clinical development strategy </em><br><em>for next-generation STAT3 inhibitor,
Apr 2, 2026
other
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
<p>HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focus
Mar 31, 2026
earnings
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
<p align="center"><em>Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026</em></p>
Mar 9, 2026
earnings_calendar
TVRD Q4 2025 Earnings After Market Close — 2026-03-09